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1. General principles
Immune-mediated inflammatory rheumatic diseases are clinical
entities with unknown etiologies, partially discovered pathogenesis,
and complex presentation. Great progress has been made in the last
few years in the understanding of the immunological mechanisms
underlying the pathogenic processes of these diseases. Together with
the development of biologic and genetic engineering techniques,
these have led to the appearance of new, highly effective therapeutic
agents that have revolutionized the treatment of such diseases.
Biologic agents are therapeutic tools produced by human genes
that are introduced in cellular cultures of various origins, using genet-
ic engineering. This results in artificial products that copy the biologic
effects of natural substances. They are fundamentally different from
usual drugs, not only because of the way they are obtained (the latter
originating from usual chemical processes), but also because of their
mechanism of action. Biologic agents have a strictly specific effect,
directed against a unique target (a molecule or a cellular receptor) [1].
Biologic agents can be grouped in several categories:
– Monoclonal antibodies (Ab), recognized by the êmab suffix
(from ímonoclonal antibodiesì), are Ab with high specificity and
affinity, produced by a single lymphocytic clone, coming from a
single stem cell. Monoclonal Ab can be:
• Chimeric – an Ab made by fusing the antigen-binding region
(variable domains of the heavy and light chains) from a mouse, with
a human constant domain (effector region). The murinic part repre-
sents about 25% of the molecule.äThe chimeric antibodies retain the
original antibodyïs antigen specificity and affinity. They are recog-
nized by the êimab suffix.
• Humanized ê in which the Fab fragment is replaced with a human
fragment, leaving just the paratope of murinic origin, which represents
about 10% of the entire molecule (recognized by the êzumab suffix).
• Human ê completely made up from human components (rec-
ognized by the êmumab suffix).
– Receptor antagonists are products with the capacity to bind to
cellular receptors, but generating no biologic response. Thus, the
receptor antagonists have affinity, but no efficacy, being biologically
inactive. They compete with the endogenous agonist of the membrane
receptor.
– Soluble receptors (recognized by the êcept suffix) are frag-
ments of the extramembrane or intracytoplasmic portion of the
membrane receptor. They have a high affinity for the receptorïs ago-
nist and bind to it before it can reach the target cell. This prevents
the agonist from reaching the cell and binding to its receptor, thus
preventing the effects of the cellular activation. 
Another classification of the biologic agents used in rheuma-
tology sorts them by molecular target:
– Anticytokine agents:
• Anti-tumor necrosis factor-α (TNF-α): monoclonal Ab
against TNF-α (Infliximab, Adalimumab, Golimumab,
Certolizumab) and soluble TNF-α receptor (Etanercept) 
• Anti-interleukin 6 (IL-6): monoclonal Ab against IL-6
(Tocilizumab)
• Anti-interleukin 1 (IL-1): monoclonal Ab against IL-1
(Anakinra)
• Anti-interleukin 17 (IL-17): completely humanized mono-
clonal Ab against IL-17A (Sekukinumab)
• Anti-interleukins 12/23 (IL-12, IL-23): humanized mono-
clonal Ab against the p40 subunit of IL-12 and IL-23 (Ustekinumab)
– Noncytokine agents:
• Anti-B lymphocyte agents:
• Monoclonal Ab against CD20, receptor found on the surface
of B lymphocytes (Rituximab)
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• Monoclonal Ab against BLyS (B-lymphocyte stimulator) ê
(Belimumab)
2. Anti-cytokine agents
2.1. Anti-TNF-α agents
TNF-α is one of the most important proinflammatory cytokines,
whose role in the pathogenesis of rheumatoid arthritis (RA), anky-
losing spondylitis (AS) and psoriatic arthritis (PsA) is extremely
important. This cytokine is responsible for many pathogenic process-
es, such as: presenting antigens, facilitating the immune response,
stimulating T lymphocytes, cellular infiltration, initiating and main-
taining inflammation, osteoclast activation and bone resorption,
matrix-metalloproteinase synthesis and articular cartilage degrada-
tion, and vascular proliferation (angiogenesis) [2–4].
This cytokine also has many physiological purposes, the most
important of which being its anti-tumoral and anti-mycobacterial
effects. TNF-α has a major role in forming and maintaining the
mycobacterial granuloma, so therapies with TNF-α blockers could
predispose to new tuberculosis (TB) infections, or latent TB activa-
tion. This imposes the necessity of thorough TB screening before
starting patients on anti-TNF-α agents.
The activity of TNF-α can be blocked either with the use of
monoclonal Ab targeted against this cytokine, or through soluble
TNF-α receptors. The cytokine is neutralized in both situations, not
being able to reach its cellular target, and the inflammatory stimu-
lus is blocked.
Infliximab is a type IgG1 chimeric monoclonal Ab, binding to
TNF-α and blocking its activity.
The usual dosage is 3–10 mg/kg (in AS it is greater than in RA,
varying between 5–10 mg/kg), administered in IV infusions at
weeks 0, 2, 6, and then every 8 weeks. If the response is insufficient
or lost, the dose can be slowly increased to the maximum allowed
one, or the administration interval can be decreased to 6 weeks.
In RA, the ATTRACT study (Anti-Tumor Necrosis Factor Trial
in Rheumatoid Arthritis with Concomitant Therapy) proved that
when given in combination with Methotrexate (MTX), Infliximab is
more efficient than MTX monotherapy in reducing clinical signs
and symptoms, improving physical function and quality of life, and
inhibiting the progression of structural damage [5, 6]. These results
have been confirmed by a wide number of studies which have
proven the long term results of Infliximab [6–8].
In AS, Infliximab was evaluated in the ASSERT study, showing
very good clinical results: 61.2% of the patients had an ASAS20%
response at 24 weeks, and vertebral inflammation evaluated using
MRI was significantly diminished [9, 10]. Numerous other studies
have afterwards underlined the efficacy of using Infliximab in AS,
not only clinically, but also by the reduction of inflammation visual-
ized using MRI and also functionally, the effects being sustained,
over periods exceeding 8 years [11]. Furthermore, Infliximab has
been proven to be efficient also in non-radiographic AS, as shown on
a subgroup of the patients in the INFAST study [12].
Infliximab has shown its use in PsA in various clinical studies,
like IMPACT II. This trial found that 58% of the patients treated
with Infliximab had an ACR20 response at 14 weeks, and that
dactylitis and enthesitis were improved [13]. Furthermore, after 
24 weeks, the cutaneous manifestations were much improved, 64%
of the patients reaching a PASI75 response. Patients treated with
Infliximab also experienced inhibition of the radiographic progres-
sion after 24 weeks, as well as functional and quality of life
improvements. The extension of the study to 2 years proved the sus-
tained therapeutic effect of Infliximab.
Adalimumab is a completely humanized anti-TNF-α monoclonal
Ab. The dose is 40 mg every 2 weeks, administered subcutaneously.
The ARMADA study proved the favorable effects of combin-
ing MTX and Adalimumab on all the clinical and radiologic param-
eters followed in RA patients [14]. Other studies have looked into
the benefic effects and the safety of the treatment with Adalimumab
combined with MTX or another disease-modifying agent or as
monotherapy, not only from a clinical point of view, but also from a
radiologic one, at 24 weeks or on the long term, in the early and late
phases of RA [15–18].
Adalimumab has been intensely studied in AS. The ATLAS
study showed that 58.2% of the patients treated with Adalimumab
reached an ASAS20% response after 12 weeks [19]. Furthermore,
there are data (from a subgroup of patients enrolled in ATLAS, but
also from other studies) which shows that Adalimumab has favor-
able clinical results in patients with advanced disease, even with
spinal ankylosis [20]. The Adalimumab dose used in AS is similar
to the one from RA, 40 mg subcutaneously every 2 weeks. In the
ABILITY-1 study, Adalimumab was efficient even in patients with
non-radiographic spondyloarthritis, thus being recommended for
this clinical entity as well [21].
Golimumab is a human anti-TNF-α monoclonal Ab, adminis-
tered subcutaneously, 50 mg once per month.
In RA, Golimumab was studied in a complex research pro-
gram, which included patients who had not been treated with dis-
ease-modifying antirheumatic drugs (DMARDs), patients who had
had no response to MTX and patients for whom another TNF-α
blocker had failed. All these studies showed that Golimumab was
able of improving symptoms and physical function and halting
structural lesions in patients with RA, not only on the short term, but
on the long term as well [22, 23].
Golimumab was evaluated in AS in the GO-RAISE study, in
which 60% of the patients obtained an ASAS20 response after 
14 weeks, and a significant improvement in BASDAI and BASFI
scores, as well in their quality of life after 6 months [24].
In PsA, Golimumab showed articular and cutaneous clinical
improvements, with the slowdown of radiologic progression, as
proven in the GO-REVEAL study and its 2 and 5 years extensions
[25, 26].
Certolizumab is a human anti-TNF-α monoclonal Ab. It is com-
posed only from the Fab fragment of the Ig and it is pegylated (coat-
ed with polyethylene glycol). When the treatment is initiated, 2 sub-
cutaneous injections are administered (400 mg) in weeks 0, 2 and 4,
and then the maintenance dose is 1 subcutaneous injection (200 mg)
every 2 weeks. Pegylation grants Certolizumab a few biological
properties: because of the higher molecular weight, the half-time is
increased, it diffuses less in normal tissues and more in regions of
inflammation, mast cell degranulation is inhibited, decreasing injec-
tion-site reactions, and the molecule does not cross the placenta,
making this drug suitable for use in pregnant women [27].
The RAPID I and RAPID II studies have proven the clinical
and radiologic efficacy of Certolizumab in RA patients who had not
responded to MTX treatment [28, 29]. There is proof that
Certolizumab is useful in RA also as monotherapy [30].
Certolizumab is the last TNF-α blocker to be approved in the
treatment of AS, the RAPID-ax-Spa study showing its clinical effi-
cacy in AS, as well as in non-radiographic spondyloarthritis [31].
Certolizumab has also been approved for the treatment of PsA.
Given 200 mg subcutaneously every 2 weeks, 58% of the patients
from the RAPID-PsA study had an ACR20 response after 12 weeks.
The therapeutic benefit was noticed very quickly, after just 1 week
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[32]. Another rapid response was noticed also for the cutaneous and
nails manifestations, for dactylitis, enthesitis, and physical function.
Etanercept is a fusion protein obtained from the combining
two identical TNF-α receptor chains (p75- type II) with the Fc
fragment of human IgG1. It has subcutaneous administration in a
dosage of 50 mg per week or 25 mg twice a week. Etanercept has
the ability to bind to soluble TNF-α molecules, preventing it
from reaching and binding its specific cellular receptors. Unlike
Infliximab, that also binds TNF-α. Etanercept only neutralizes
soluble, not membrane-bound, TNF-α, leading to a milder
blockade.
Etanercept has been thoroughly studied in RA, having its effi-
cacy proven not only in association with MTX, but also as
monotherapy, in patients with no response to MTX or in those who
had never attempted MTX. The TEMPO study (Trial of
Etanercept and Methotrexate with radiographic Patient
Outcomes) showed the good results of the Etanercept ê MTX
combination regarding clinical and radiologic outcomes [33].
Other studies focused on the benefits of Etanercept in both long
term and early arthritis [34, 35].
In AS, Etanercept has shown its clinical use, measured by sig-
nificant decreases in the BASDAI (Bath Ankylosing Spondylitis
Disease Activity Index), BASFI (Bath Ankylosing Spondylitis
Functional Index) and BASMI (Bath Ankylosing Spondylitis
Metrology Index) scores [36]. Etanercept also diminishes vertebral
inflammation (measured using MRI), has long term efficacy and
works in non-radiographic spondyloarthritis, as shown by the
ESTHER study [37]. The dose used in AS is similar to that for RA,
50 mg subcutaneously once a week.
Etanercept has been studied in PsA as well. In the first study,
59% of the patients treated with Etanercept reached an ACR20
response and 23% a PASI75 response at 24 weeks, at the same time
experiencing improvements in physical function, quality of life, and
radiologic progression [38]. The long-term extension of this trial
showed that the therapeutic effects are maintained. The PRESTA
study showed that the subcutaneous dose of 50 mg per week has sig-
nificant clinical benefits regarding ACR responses and enthesitis
improvements [39].
TNF-α blockers have shown to be useful also for the extra-
articular manifestations of spondyloarthritis. Infliximab and
Adalimumab helped decrease uveitis episodes, a benefit that was
not found with Etanercept [40]. Recent data suggests that
Golimumab might also have a role in this regard (41). When the
intestinal effects were studies, Infliximab and Adalimumab have
proven to be helpful in diminishing the gastro-intestinal manifesta-
tions of both spondyloarthritis and Crohn disease, with no results
using Etanercept [41].
TNF-α blockers are safe, the main adverse effects being 
[8, 42]:
• Higher risk for infections, especially TB;
• Higher risk for neoplasia, although data seems to show that
the risk is not higher than in RA alone; lymphoma does appear more
often, nevertheless;
• Increases the severity of heart failure, this being the reason
why it is contraindicated in patients with stage III and IV heart fail-
ure;
• Demyelinating disease – rarely;
• Anti-DNAds antibodies and even lupus-like syndrome;
• Allergic reactions;
• Immunogenicity, with the development of antibodies against
the biological agent.
TNF-α blockers are very efficient, but there are 35–40% of
patients who do not respond to this therapy, prompting the need for
medications with different modes of action.
2.2. IL-6 blockers
IL-6 is also a proinflammatory cytokine with an important role
in the pathogenesis of RA, not only locally, but also systemically. It
enhances the activation, differentiation, and proliferation of B lym-
phocytes, it stimulated Ig synthesis, it favors the differentiation of
cytotoxic T lymphocytes and Th lymphocytes and IL-17 synthesis,
leading to acute inflammation, chronic inflammation and maintaining
the immune response [2]. Within the joint, IL-6 contributes to the pro-
liferation of synoviocytes, angiogenesis, pannus formation, and bone
and cartilage destruction. IL-6 also has systemic effects: it stimulates
the synthesis of acute phase reactants in the liver, it causes anemia by
increasing the hepatic production of hepcidin (which traps iron with-
in macrophages), it causes fatigue by affecting the hypothalamo-pitu-
itary axis, and it increases the cardiovascular risk by influencing lipid
metabolism and through its proinflammatory effects. 
Tocilizumab is a monoclonal Ab targeted against IL-6 receptor,
to which it binds, blocking the cytokine and its effects. Tocilizumab
is administered in IV perfusions in doses of 8 mg/kg, monthly. The
product has recently become available in subcutaneous administra-
tion, with the dose of 162 mg/week. The benefits of Tocilizumab
have been proven in many clinical studies, including patients with
inadequate responses to MTX or other synthetic DMARDs, patients
who were never treated with MTX or patients with no response to
anti-TNF-α agents. Tocilizumab brought clinical, functional, radio-
logic, and quality of life improvements, not only in combination
with MTX, but also as monotherapy [43–45]. Tocilizumab is con-
sidered the biological agent with the most solid evidence regarding
its use as monotherapy [46].
2.3. IL-1 blockers
IL-1 is a proinflammatory cytokine whose actions are similar to
TNF-α. So far, there is just one IL-1 blocker approved in RA treat-
ment, Anakinra, a human IL-1 receptor antagonist recombinant.
Although Anakinra has studies proving its benefit in the treatment
of RA and was the first biological agent with a different mode of
action than TNF-α blockers, it has fallen into disuse. Its efficiency
is less than that of newer biological agents and its mode of admin-
istration (daily subcutaneous injections) is inconvenient [47].
2.4. IL-17 blockers
At the start of 2016, the first biological agent against IL-17 was
approved, Sekukinumab, a completely humanized monoclonal Ab,
with two indications: AS and PsA.
The approval of Sekukinumab in AS was based on many clini-
cal studies that showed clinical and functional benefits, expressed by
improvements of at least 20% of the ASAS and ACR20 scores after
16 and 24 weeks [48]. These results were found both in patients who
had never been treated with biological agents, and in those with no
response to TNF-α blockers. Sekukinumab is administered subcuta-
neously, 150 mg in weeks 0, 1, 2 and 3, followed by a monthly main-
tenance dose. If the therapeutic response is not satisfying, the dosage
can be increased to 300 mg monthly. The safety profile of the drug is
good, further data on this aspect remains to be obtained.
As in the case of AS, Sekukinumab was recently approved for
the treatment of PsA [49]. FUTURE I and FUTURE II studies
showed good therapeutic responses. Greater percentages of patients
treated with Sekukinumab obtained an ACR20 response at 
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24 weeks, when compared with placebo. The safety profile was
good as well, the most frequent adverse reactions being respiratory
infections. The dosage is similar to that used for AS.
2.5. IL12/23 blockers
Ustekinumab was the first biological agent with another mode
of action than TNF-α blockers to be approved in PsA. It is a human-
ized monoclonal Ab targeted against the p40 subunit of IL-12 and
IL-23 [50]. In PSUMMIT-1 study, Ustekinumab was administered
to patients who had not previously received TNF-α blockers. The
results showed significant clinical improvements after 1 year of
treatment, and the safety profile was favorable. The PSUMMIT-2
study included both patients previously treated with anti-TNF-α
agents and some who had not taken such drugs. Both patients
groups had clinical improvements (regarding articular and skin
manifestations, dactylitis, enthesitis, and fatigue), as well as signif-
icant functional benefits after 24 weeks, the effects being persistent
after 1 year of treatment. PSUMMIT-1 and two other studies
showed that Ustekinumab could be an alternative to TNF-α block-
ers, having high efficacy and a good safety profile.
3. Non-cytokinic therapeutic agents
3.1. T lymphocyte blockers
One of the activation pathways for the T lymphocyte is the pair
composed from the costimulatory molecule complex CD80/86
found on the antigen presenting cell and the CD28 receptor on the
T lymphocytes. The binding of CD80/86 to CD28 activates the 
T lymphocyte, while the binding of CD80/86 to the CTLA-4 recep-
tor inhibits it.
Abatacept is a completely humanized, recombinant soluble
receptor, obtained through the fusion of the extracellular domain of
CTLA-4 with the Fc fragment of IgG1.
This biological agent is so far approved only in the treatment of
RA and it is the first representative of a new class of drugs target-
ing the activation of the T lymphocyte. Abatacept binds to CD80/86
on the antigen-presenting cell with a much higher affinity than
CD28, thus blocking the costimulation and activation of the T lym-
phocyte. Through its selective action on CD80/86, Abatacept allows
T lymphocyte activation through other pathways, thus its stimula-
tion is not compromised. Abatacept is a biological agent that can be
administered in perfusions (500–1000 mg in weeks 0, 2, 4, then
monthly), as well as subcutaneously (125 mg weekly). Randomized
clinical studies have shown that Abatacept, in combination with
MTX, has beneficial effects on signs and symptoms, but also on
function and structural destruction in RA, in naÏve MTX patients or
in patients with inadequate response to MTX [51]. The long-term
extensions of these studies proved the persistent therapeutic effect
of Abatacept. Furthermore, Abatacept benefitted from a head-to-
head trial, the AMPLE trial, being compared to Adalimumab, prov-
ing similar therapeutic effects and safety profiles [52].
3.2. B lymphocyte blockers
The B lymphocyte is an important íactorì on the stage of inflam-
matory rheumatic diseases pathogenesis, being involved in numerous
immunopathogenic processes: it is an antigen presenting cell, con-
tributing to the activation of the T lymphocyte, it produces proinflam-
matory cytokines, and it synthesizes autoantibodies [53]. CD20 is a
receptor found only on the surface of B lymphocytes, not on stem cells
or on plasmocytes; thus, blocking this receptor causes the depletion of
peripheral B lymphocyte populations through many mechanisms: cel-
lular cytotoxicity, complement activation and apoptosis stimulation.
Rituximab is a chimeric monoclonal Ab against the CD20
receptor found on the surface of the B lymphocyte, initially used in
the treatment of non-Hodgkin lymphomas.
Clinical trials have shown than Rituximab in combination with
MTX is efficient in the treatment of RA, relieving clinical symp-
toms and stopping the progression of structural lesions [54, 55]. It is
administered IV, the dose is 1000 mg, repeated after 2 weeks. A new
cycle of 2 perfusions is administered after 6 months. The safety pro-
file of Rituximab is good, the most frequent adverse reactions being
those related to the IV perfusion and a slightly higher incidence of
infections. So far, Rituximab is recommended for patients with no
response to an anti-TNF-α agent, but in some circumstances (recent
lymphoma history, latent TB with chemoprophylaxis contraindica-
tion, TB endemic region, and demyelinating disease history) it can
also be used as a first-line biological agent.
Rituximab has shown favorable clinical effects in a significant
percentage of systemic lupus erythematosus (SLE), irrespective of
the presence of nephropathy, in many studies and registries. Two
randomized trials (EXPLORER and LUNAR) failed to prove its
superiority over the conventional therapy [56], so Rituximab has not
yet been approved in the treatment of LES.
In 2011, the FDA approved the use of Rituximab in granulo-
matosis with polyangiitis and in microscopic polyangiitis, thus
becoming the first biological agent with these indications [57]. The
RAVE study (Rituximab in ANCA-Associated Vasculitis) was a
multicentric, randomized, double-blind, non-inferiority study that
evaluated the efficacy and safety of Rituximab in comparison to the
standard therapy in these ANCA-Associated vasculitis. The main
objective was obtaining remission after 6 months, in the absence of
steroids [58]. This objective was reached by 64% of patients treat-
ed with Rituximab and by 53% of those on the standard therapy,
thus is was proven to be non-inferior. There were no differences
regarding side effects between the two patients groups.
Furthermore, patients treated with Rituximab obtained better
results after a relapse than those on Cyclophosphamide. The long-
term data showed that in the severe cases of ANCA-Associated
vasculitis, a single weekly dose of 375 mg/m2 of Rituximab, for 
4 weeks, associated with corticotherapy, was not inferior to the
conventional treatment of steroids and Cyclophosphamide, fol-
lowed by a maintenance treatment with Azathioprine for remission
after 18 months [59].
In 2011, FDA approved the first biologic agent in SLE,
Belimumab [60]. This is a monoclonal anti-BLyS (B-lymphocyte
stimulator) or BAFF (B-cell activating factor) Ab, a molecule with
an essential contribution to the proliferation, activation and survival
of B lymphocytes. This molecule can be secreted by more cell
types, such as: macrophages, monocytes, medullary stromal cells,
and synoviocytes [61]. In SLE, BLyS synthesis is increased, thus
administering a monoclonal anti-BLyS Ab can bring therapeutic
effects.
The efficacy and safety of Belimumab have been studied in
many clinical trials. The BLISS52 and BLISS76 studies showed
that Belimumab, administered IV in a dose of 10 mg/kg once a
month, added to the standard treatment, proved better therapeu-
tic responses than the standard treatment alone, evaluated
through SRI (SLE Responder Index) after 1 year of treatment
[62, 63]. Using Belimumab led to improvements in cutaneous
and articular signs and symptoms, as well as in serology.
Because these studies excluded patients with severe nephropa-
thy, Belimumab is so far recommended only in SLE without
nephropathy. Trials to evaluate its efficacy in patients with
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nephropathy are ongoing. Furthermore, Belimumab was proven
to be well tolerated, but further long-term data is required to bet-
ter understand its safety profile.
4. Summary of biological treatments available
In summary, immune-mediated inflammatory rheumatic dis-
eases that benefit from treatment options with biological agents are:
• RA:
• anti-TNF-agents: Infliximab, Adalimumab, Certolizumab,
Golimumab, Etanercept
• anti-IL-6-agents: Tocilizumab
• anti-IL-1-agents: Anakinra
• anti-B lymphocyte-agents: Rituximab
• anti-costimulation molecules agents: Abatacept
• AS:
• anti-TNF-agents: Infliximab, Adalimumab, Certolizumab,
Golimumab, Etanercept
• anti-IL-17-agents: Sekukinumab
• PsA:
• anti-TNF-agents: Infliximab, Adalimumab, Certolizumab,
Golimumab, Etanercept
• anti-IL-17-agents: Sekukinumab
• anti-IL-12/23-agents: Ustekinumab
• SLE:
• anti-BLyS-agents: Belimumab 
• some ANCA-associated vasculitides:
• anti-B lymphocyte-agents: Rituximab
5. Clinical practice in Romania
In emerging market regions such as Central and Eastern
Europe, disparity due to economic and social factors provides chal-
lenges to achieving optimal monitoring and treatment of immune-
mediated inflammatory diseases. 
Several countries of this region, including Romania, have
adapted «treat to target» guidelines that are in line with the current
EULAR Recommendations [64]. Following consensus guidelines
for early, aggressive treatment to target with biologic agents will be
critical for narrowing the treatment gap in this region [65]. 
Consequently, in Romania several opportunities for tightening
treatment differences in these diseases were followed: implement-
ing focused patient education initiatives along with physician edu-
cational programs and healthcare provider education to increase
overall awareness of the importance of early diagnosis and treat-
ment, providing regulators and healthcare payers with this informa-
tion along with health-economic data in order to convince these
authorities to maximize early treatment with biologics. 
Another important step was the development of a national reg-
istry, «The Romanian Registry of Rheumatic Diseases» (RRBR).
This is an electronic application that includes data of all RA, AS and
PsA patients treated with biologics in Romania. In this Registry, ini-
tiated in February 2013, multiple variables are collected: demo-
graphics, diseases history, therapies, diseases activity, adverse
events, lab results, PRO, and others, in order to provide data for
these patients in our country [66]. The application belongs to the
Association «Romanian Registry of Rheumatic Diseases», a non-
profit organization initiated by the Romanian Society of
Rheumatology. Data is entered in the Registry by the rheumatolo-
gist in charge of the patientïs care, after the patient signs an
informed consent form. 
Including patients in this registry is mandatory, in order to
obtain reimbursement for biologics. At the beginning of 2017,
almost 10000 patients (more than 60% being RA patients) were
included in the Registry [67]. 
In Romania, the cost of biological treatment for RA, AS and
PsA is fully reimbursed by the National Insurance House (NIH) for
eight biologic agents [68]: 
– five TNF-α blockers for RA, AS and PsA (Infliximab, includ-
ing biosimilars, Etanercept, Adalimumab, Golimumab, Certolizumab)
– for RA, there is also reimbursement for three biologic agents
with a different mode of action: Rituximab, Tocilizumab and Abatacept. 
At the moment, no biological treatment for other immune-
mediated inflammatory rheumatic diseases (like SLE or vasculitis)
is reimbursed. 
The NIH has established the criteria which must be fulfilled by
the patients in order to be eligible for biological treatment [69, 70]:
5.1. Criteria for biological treatment in RA
For RA, the patient must have an active disease, despite treat-
ment with at least two synthetic DMARDs (mainly methotrexate,
leflunomide, or sulfasalazine; methotrexate is a mandatory option,
if there is no proven contraindication) at maximal doses, for at least
12 weeks each, and have no contraindications for biological thera-
py. An active disease is defined as a Disease Activity Score with 
28 joints (DAS28) over 5.1, including a total of at least five painful
and swollen joints, and an increased acute phase reactant: erythro-
cyte sedimentation rate (ESR) >28mm/hour or C reactive protein
(CRP), quantitative assay, over 3 times the upper limit. 
Outcome assessments are conducted after 6 months of treat-
ment, using DAS28, Simplified Disease Activity Index (SDAI), and
Clinical Disease Activity Index (CDAI) as outcome measures. 
A patient is considered to be a responder if DAS28 improves with
more than 1.2 or achives a value <3.2) and responders are approved
for another 6 months. Treatment outcomes are re-assessed every 
6 months, thereafter. If a patient is found to be a non-responder,
switching to another biologic agent is recommended. Importantly, a
shared decision between patient and physician determines the pre-
scribed switch. 
5.2. Criteria for biological treatment in AS
AS patients must have severe, active disease define by: BAS-
DAI repeatedly over 6, Ankylosing Spondylitis Disease Activity
Score – ASDAS – over 2.5, and an increased acute phase reactant:
ESR >28mm/hour or CRP, quantitative assay, over 3 times the upper
limit), not controlled with traditional therapies at maximally tolerat-
ed doses (at least two nonsteroidal anti-inflammatory drugs –
NSAIDs – for 6 weeks each in patients with axial disease). For
patients with peripheral disease, sulfasalazine for at least 4 months
at maximal doses is also mandatory, as well as local injections of
glucocorticoids for active peripheral arthritis or enthesitis.
Coxofemoral joint involvement and extraarticular manifestations
are factors which allow the initiation of biological therapy earlier,
with lower disease activity scores (BASDAI >4, ASDAS >2.1).
5.3. Criteria for biological treatment in PsA
To be considered for biological therapy, the disease activity
must be high (Disease Activity in Psoriatic Arthritis – DAPSA –
score over 28), with at least 5 tender and swollen joints, and CRP,
quantitative assay, over 3 times the upper limit. Traditional treat-
ments, administered according to the guidelines, in maximally tol-
erated doses, must be proven inefficient for controlling the disease:
at least two synthetic DMARDs for 12 weeks each (methotrexate is
a mandatory option, if there is no proven contraindication), at least
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two NSAIDs for 6 weeks each for axial arthritis, enthesitis, or
dactylitis, or local injections of glucocorticoids for enthesitis or
dactylitis. If there are negative prognostic factors associated with
PsA, a treatment with one synthetic DMARD for 12 weeks is
enough for the switch to biological agents.
6. Conclusions
There are several emerging market regions ê including
Romania ê that have committed to these types of initiatives, with the
goal of decreasing the burden of immune-mediated inflammatory
diseases. 
A second important step in decreasing treatment disparities is for
rheumatologists to adapt their strategies to fit the ACR/EULAR guide-
lines for treating to target [71]. Romania has been included in the «treat
to target» dialogue, and many rheumatologists in this country have
shifted their approach on the management of these diseases to fit the
guidelines. However, there is much to be done for the purposes of
reimbursement of all biological agents and extension of the reim-
bursement of this treatment to other inflammatory rheumatic diseases.
As more nations in Central and Eastern Europe adapt these
approaches, patients with immune-mediated inflammatory diseases
will be able to achieve the best treatment outcomes.
So far, the use of biological agents in rheumatology is an
extremely dynamic process. The range of these therapeutic
instruments is permanently widened by the addition of new
drugs with new indications. In diseases like RA, AS or PsA there
are over 15 years of experience with many such agents from dif-
ferent classes, and their numbers keep on increasing. For other
diseases, like SLE and vasculitis, this journey is just beginning,
the experience in the use of biological agents being way less.
There are other rheumatic diseases, like scleroderma, nonspecif-
ic inflammatory myopathies, Sjö gren syndrome, or other vas-
culitis, for which no biological agents have been approved so far,
but many studies are still underway concerning them.
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